We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Inhaled Fluticasone Propionate: Effect on Parameters of Bone Metabolism in Patients With Mild to Moderate Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00409630
Recruitment Status : Withdrawn (Sponsor decided against going forward with the study.)
First Posted : December 11, 2006
Last Update Posted : April 12, 2012
Information provided by:
University of Kansas Medical Center

Brief Summary:
Subjects between the ages of 20-45 with mild to moderate asthma will be recruited. Following consent, subjects will undergo an evaluation to assure no underlying metabolic bone disease. Individuals will be treated with inhaled fluticasone low or high dose, daily for 3 months. Serum and urine biochemical markers of bone metabolism will be collected at baseline and monthly for three months. Adherence to study medication and adverse events will be collected at monthly intervals. Differences between fluticasone low and high dose treated individuals will be analyzed between groups and compared with baseline values.

Condition or disease Intervention/treatment Phase
Asthma Drug: fluticasone Not Applicable

Detailed Description:
This study will be a prospective randomized trial. Thirty subjects with mild to moderate asthma will receive inhaled fluticasone propionate. Fifteen patients will receive low dose inhaled fluticasone 88 mcg twice daily. Fifteen patients will receive inhaled fluticasone 440 mcg twice daily. The primary outcome will be biochemical markers of bone turnover. These will include 1) serum biochemical markers of bone formation [osteocalcin, bone specific alkaline phosphatase (ALP) and procollagen I C-terminal propeptide (PICP)] and 2) markers of bone resorption, serum collagen type 1 C-Telopeptide (CTx) urinary N-telopeptide (NTx) and immunoreactive free deoxypyridinoline (iFDpd)]. Secondary endpoints will include, parathyroid hormone (PTH), Urinary Calcium/creatinine, and adverse events.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Inhaled Fluticasone Propionate: Effect on Parameters of Bone Metabolism in Patients With Mild to Moderate Asthma

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Primary Outcome Measures :
  1. Bone markers after 3 months of fluticasone

Secondary Outcome Measures :
  1. Skin thickness measured by ultrasound biomicroscopy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Before any study-specific procedure, the appropriate informed consent must be signed
  • Male and premenopausal female subjects
  • Age ≥ 20 years through ≤ 45 years of age
  • Documented History of Mild to moderate Asthma as defined by the NHLBI guidelines:

    • Mild Intermittent - FEV1 or PEF >/= 80% predicted, PEF variability <20%.
    • Mild persistent - FEV1 or PEF >80% predicted, PEF variability, >/= 20-30%
    • Moderate persistent - FEV1 or PEF>60%-<80% predicted, PEF variability >30%
  • Ambulatory status

Exclusion Criteria:

  • Smoking
  • Current use of inhaled glucocorticoid therapy or use within the past 3 months. Current use of leukotriene modifiers and/or inhaled bronchodilators will be allowed.
  • Use of oral glucocorticoids within the past year.
  • Pregnant or breast feeding.
  • Last menstrual period greater than 1 year ago
  • Diabetes Mellitus type 1 or 2
  • Paget's Disease, osteomalacia, hyperparathyroidism, renal osteodystrophy or other metabolic bone diseases
  • History of hyperthyroidism within 1 year of randomization
  • AST or ALT > 2x upper limit of normal
  • Serum creatinine greater than 2.0 mg/DL
  • History of cancer within the previous 5 years, (exceptions: excised superficial lesions, such as basal or squamous cell carcinoma of the skin.
  • The use of thiazide diuretics or anticonvulsant medications.
  • Subject is currently enrolled or has received investigational drug within 30 days prior to randomization
  • Use of (within 3 months of randomization) hormones, SERMS, calcitonin, PTH (Forteo)
  • Use of (within 6 months of randomization) bisphosphonates, (Fosamax, Actonel, Didronel), Vitamin D 50,000 iu
  • Use of (within 12 months of randomization) corticosteroids and/or inhaled steroids, anticonvulsants. Topical and intra-articular steroids are allowed except for topical steroids applied to the area where measurements of skin thickness will be made; ie.
  • Use of (within 24 months of randomization) I.V. Zometa or I.V. Aredia
  • Subject has any disorder that compromises the ability of the subject to give written consent and/or to comply with study procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00409630

Sponsors and Collaborators
University of Kansas
Layout table for investigator information
Principal Investigator: Leland Graves, MD University of Kansas Medical Center
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00409630    
Other Study ID Numbers: 10384
First Posted: December 11, 2006    Key Record Dates
Last Update Posted: April 12, 2012
Last Verified: April 2012
Keywords provided by University of Kansas Medical Center:
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents